Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q3

2342.TEDINET S100Q04J
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 35
MetricValuePeriodScopeSource row
Revenue¥8.5bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥12.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥153m2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥1.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥385m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.7bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥344m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥1.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥182m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.9bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥803m2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥171m2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥795m2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥10.9bnat 2022-12-31Cons.Assets
Total assets¥10.4bnat 2022-03-31Cons.Assets
Total assets¥10.2bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥4.2bnat 2022-12-31Cons.Liabilities
Total liabilities¥3.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.6bnat 2022-03-31Cons.Net assets
Net assets / equity¥5.6bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥4.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥10.812022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥7.542022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥109.522021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.572021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-10.552021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥109.312021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥46.462021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio60.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.7%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥4m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥2m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥157m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥132m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥179m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥310m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥9m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥9m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥138m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥3.9bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.9bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥9m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥5.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥5.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥491,000
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥203m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥9.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥9m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 368
ItemContextValueUnit
Accounts payable tradePrior1YearInstant256013000JPY
Accounts payable tradeCurrentQuarterInstant444376000JPY
Accounts payable otherPrior1YearInstant424600000JPY
Accounts payable otherCurrentQuarterInstant290853000JPY
Short term loans payablePrior1YearInstant390000000JPY
Short term loans payableCurrentQuarterInstant270000000JPY
Current portion of bondsPrior1YearInstant14000000JPY
Current portion of bondsCurrentQuarterInstant14000000JPY
Current portion of long term loans payablePrior1YearInstant323939000JPY
Current portion of long term loans payableCurrentQuarterInstant468119000JPY
Income taxes payablePrior1YearInstant299464000JPY
Income taxes payableCurrentQuarterInstant16471000JPY
Advances receivedPrior1YearInstant775539000JPY
Advances receivedCurrentQuarterInstant620457000JPY
Provision for bonusesPrior1YearInstant16785000JPY
Provision for bonusesCurrentQuarterInstant3163000JPY
Provision for loss on order received clPrior1YearInstant148000JPY
Provision for loss on order received clCurrentQuarterInstant－JPY
Other clPrior1YearInstant158932000JPY
Other clCurrentQuarterInstant147826000JPY
Current liabilitiesPrior1YearInstant2659423000JPY
Current liabilitiesCurrentQuarterInstant2275269000JPY
Bonds payablePrior1YearInstant151000000JPY
Bonds payableCurrentQuarterInstant144000000JPY
Long term loans payablePrior1YearInstant880560000JPY
Long term loans payableCurrentQuarterInstant1676093000JPY
Long term accounts payable otherPrior1YearInstant43697000JPY
Long term accounts payable otherCurrentQuarterInstant31596000JPY
Net defined benefit liabilityPrior1YearInstant24762000JPY
Net defined benefit liabilityCurrentQuarterInstant39713000JPY
Other nclPrior1YearInstant44484000JPY
Other nclCurrentQuarterInstant32475000JPY
Noncurrent liabilitiesPrior1YearInstant1144504000JPY
Noncurrent liabilitiesCurrentQuarterInstant1923877000JPY
LiabilitiesPrior1YearInstant3803928000JPY
LiabilitiesCurrentQuarterInstant4199147000JPY
Capital stockPrior1YearInstant50000000JPY
Capital stockCurrentQuarterInstant50000000JPY
Capital surplusPrior1YearInstant4109106000JPY
Capital surplusCurrentQuarterInstant3879142000JPY
Retained earningsPrior1YearInstant2657874000JPY
Retained earningsCurrentQuarterInstant2739027000JPY
Treasury stockPrior1YearInstant-300325000JPY
Treasury stockCurrentQuarterInstant-76915000JPY
Shareholders equityPrior1YearInstant6516656000JPY
Shareholders equityCurrentQuarterInstant6591254000JPY
Valuation difference on available for sale securitiesPrior1YearInstant1066000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant-5987000JPY
Foreign currency translation adjustmentPrior1YearInstant14851000JPY
Foreign currency translation adjustmentCurrentQuarterInstant22264000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass